Literature DB >> 11262455

Troglitazone is a competitive inhibitor of 3beta-hydroxysteroid dehydrogenase enzyme in the ovary.

S Gasic1, M Nagamani, A Green, R J Urban.   

Abstract

OBJECTIVE: Troglitazone is a potent inhibitor of progesterone release from porcine granulosa cells. This is associated with a marked increase in pregnenolone secretion, implicating inhibition of the 3beta-hydroxysteroid dehydrogenase enzyme. This study determined whether troglitazone is a direct inhibitor of 3beta-hydroxysteroid dehydrogenase activity. STUDY
DESIGN: Homogenates of porcine granulosa cells underwent classic enzyme kinetic analysis through Lineweaver-Burke and Dixon plotting. Human ovarian homogenates were also assayed for the effects of troglitazone on 3beta-hydroxysteroid dehydrogenase enzyme activity. Enzyme kinetics data were analyzed by the HyperKinetics software program. Analysis of variance was used to determine statistical significance for human ovarian homogenate experiments.
RESULTS: In porcine granulosa cells Lineweaver-Burke analysis found that troglitazone inhibition of 3beta-hydroxysteroid dehydrogenase enzyme activity was competitive in nature, with 5 microg/mL troglitazone increasing the apparent Michaelis constant from 1.3 to 4.3 micromol/L (no change in maximum velocity). Dixon plot analysis demonstrated that the inhibition constant for troglitazone of 3beta-hydroxysteroid dehydrogenase is approximately 6.5 microg/mL, which is in the same order of magnitude as its therapeutic concentration in blood. Troglitazone also significantly decreased the activity of 3beta-hydroxysteroid dehydrogenase in homogenates of human ovarian tissue.
CONCLUSION: We conclude that troglitazone can inhibit steroidogenesis in the ovary by direct competitive inhibition of 3beta-hydroxysteroid dehydrogenase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11262455     DOI: 10.1067/mob.2001.111242

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  14 in total

Review 1.  Targets to treat metabolic syndrome in polycystic ovary syndrome.

Authors:  Shruthi Mahalingaiah; Evanthia Diamanti-Kandarakis
Journal:  Expert Opin Ther Targets       Date:  2015-10-21       Impact factor: 6.902

2.  Genetic variants in peroxisome proliferator-activated receptor gamma influence insulin resistance and testosterone levels in normal women, but not those with polycystic ovary syndrome.

Authors:  Heath J Antoine; Marita Pall; Belynda C Trader; Yii-Der I Chen; Ricardo Azziz; Mark O Goodarzi
Journal:  Fertil Steril       Date:  2006-12-04       Impact factor: 7.329

3.  Metabolic and hormonal changes induced by pioglitazone in polycystic ovary syndrome: a randomized, placebo-controlled clinical trial.

Authors:  Vanita R Aroda; Theodore P Ciaraldi; Paivi Burke; Sunder Mudaliar; Paul Clopton; Susan Phillips; R Jeffrey Chang; Robert R Henry
Journal:  J Clin Endocrinol Metab       Date:  2008-11-04       Impact factor: 5.958

4.  Osteoblast-activating peptide exhibits a specific distribution pattern in mouse ovary and may regulate ovarian steroids and local calcium levels.

Authors:  Ahmed E Noreldin; Mahmoud S Gewaily; Islam M Saadeldin; Mosleh M Abomughaid; Asmaa F Khafaga; Yaser H Elewa
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

5.  Effect of chronic treatment with Rosiglitazone on Leydig cell steroidogenesis in rats: in vivo and ex vivo studies.

Authors:  Janaína A Couto; Karina L A Saraiva; Cleiton D Barros; Daniel P Udrisar; Christina A Peixoto; Juliany S B César Vieira; Maria C Lima; Suely L Galdino; Ivan R Pitta; Maria I Wanderley
Journal:  Reprod Biol Endocrinol       Date:  2010-02-09       Impact factor: 5.211

Review 6.  Minireview: Nuclear receptor-controlled steroid hormone synthesis and metabolism.

Authors:  Jinhan He; Qiuqiong Cheng; Wen Xie
Journal:  Mol Endocrinol       Date:  2009-09-17

7.  Decreased androgen levels and improved menstrual pattern after angiotensin II receptor antagonist telmisartan treatment in four hypertensive patients with polycystic ovary syndrome: case series.

Authors:  Mojca Jensterle; Andrej Janez; Bojan Vrtovec; Helena Meden-Vrtovec; Marija Pfeifer; Janez Prezelj; Tomaz Kocjan
Journal:  Croat Med J       Date:  2007-12       Impact factor: 1.351

8.  Rosiglitazone and pioglitazone alter aromatase kinetic properties in human granulosa cells.

Authors:  Takako Araki; Miroslava Varadinova; Michael Goldman; Zev Rosenwaks; Leonid Poretsky; Donna Seto-Young
Journal:  PPAR Res       Date:  2011-12-19       Impact factor: 4.964

9.  Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells.

Authors:  Qiuju Chen; Xiaoxi Sun; Junling Chen; Linan Cheng; Jian Wang; Yongwei Wang; Zhaogui Sun
Journal:  Reprod Biol Endocrinol       Date:  2009-12-09       Impact factor: 5.211

10.  Activation of PPARγ by Rosiglitazone does not negatively impact male sex steroid hormones in diabetic rats.

Authors:  Mahmoud Mansour; Elaine Coleman; John Dennis; Benson Akingbemi; Dean Schwartz; Tim Braden; Robert Judd; Eric Plaisance; Laura Ken Stewart; Edward Morrison
Journal:  PPAR Res       Date:  2009-06-11       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.